Just Published: Advanced imaging of Biochemically-resistant Prostate cancer with PET, MRI, and Radiomics


IAG’s Team published a new article ”Advanced imaging of Biochemically-resistant Prostate cancer with PET, MRI, and Radiomics‘, Frontiers in Oncology, August 2020

IAG, Image Analysis Group’s  article ‘Advanced imaging of Biochemically-resistant Prostate cancer with PET, MRI, and Radiomics‘ just been published in the Elsevier’s  journal  ‘Frontiers in Oncology‘, online access here.

‘In today’s changing enviroment, Advanced Imaging and AI make a veritable impact in drug development’, said Dr. Shaikh, head of IAG’s Advanced Imaging and Radiomics

Prostate cancer is the second most common type of cancer occurring in men and a major cause of morbidity and mortality. Medical imaging plays a major role in the management of this condition and includes Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET).

Biochemically-resistant prostate cancer is difficult to manage. In this paper, we discuss the increasingly important role that multiparametric MRI and PET/CT imaging play in its management and development novel therapeutics. MRI is now certain to become the future cornerstone of the risk-stratification process for men at risk of early prostate cancer.  A multi-parametric magnetic resonance imaging (mpMRI) scan is a special type of scan that creates more detailed pictures of the prostate than a standard MRI scan. It does this by combining four different types of image sequences.

The use of PET/CT for this indication goes beyond 18F-fluorodeoxyglucose (FDG) and 18F-sodium fluoride (NaF) to include highly specific tracers – 18F-fluciclovine (Axumin), 18F- or 68Ga-PSMA and 18F-DCFPyL radiotracers.

‘Quantitative imaging strategies, such as Radiomics, which have been leveraged to extract microstructural and molecular signatures that guide the precision diagnostics and therapeutics for prostate cancer are also reviewed in this article’, said Dr. Olga Kubassova, CEO of IAG.

IAG’s expert team are working with academic and clinical collaborators as part of Re-IMAGINE project and biotech and pharma companies to bring these strategies to accelerate drug development.

Authors: Faiq Shaikh, Diana Dupont-Roettger, Jamshid Dehmeshki, Olga Kubassova and Mohammed I. Quraishi

Online Access: https://www.frontiersin.org/articles/10.3389/fonc.2020.01359/full

Ref: Front. Oncol., 19 August 2020 | https://doi.org/10.3389/fonc.2020.01359

About IAG: 

IAG, Image Analysis Group is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. www.ia-grp.com

 For more information, please reach to <imaging.experts@ia-grp.com>